Dieldrin: Carcinogenic Potency Database

Dieldrin (CAS 60-57-1)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary

Rat Target Sites		Mouse Target Sites		TD₅₀ (mg/kg/day)
Male	Female	Male	Female	Rat	Mouse
no positive	no positive	liv	liv	no positive	0.912^m,P

Hamsters: Cancer Test Summary

Hamster Target Sites		TD₅₀ (mg/kg/day)
Male	Female	TD₅₀ (mg/kg/day)
no positive	no positive	no positive

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD₅₀) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.

Target Site Codes: liv = liver. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.

TD₅₀: Our standardized measure of carcinogenic potency, TD₅₀, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD₅₀ value is a Harmonic Mean calculated using the TD₅₀ value from the most potent target site in each positive experiment.

Superscripts: m = There is more than one positive experiment in the species, and TD₅₀ values from each positive experiment are used in the calculation of the reported Harmonic mean of TD₅₀. P = 100% of dosed animals had tumors at a target site in an experiment in this species.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD₅₀) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD₅₀ estimation for a standard lifespan. See Methods for other details.

TD₅₀ provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD₅₀ values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Dieldrin: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD₅₀; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code



DIELDRIN   60-57-1
2092 H f syg eat 23m26 1000                          0    2.09mg  6.27mg  18.8mg                          Cabral;clet,6,241-246;1979
 liv hpt e      176.mg * P<.3    -  28.7mg n.s.s.   0/6     0/2     0/8     1/9
 lun tum e      no dre   P=1.    -  11.8mg n.s.s.   0/39    0/32    0/34    0/38
 tba mix e      355.mg * P<.6    -  54.3mg n.s.s.   5/39    1/32    5/34    5/38
2093 H m syg eat 26m26 1000                          0    1.84mg  5.52mg  16.6mg
 liv hpt e      198.mg * P<.4    -  32.2mg n.s.s.   0/2     0/3     0/5     1/13
 lun ade e      732.mg * P<.2    -  119.mg n.s.s.   0/40    0/32    0/32    1/40
 tba mix e      69.9mg * P<.05   -  26.5mg n.s.s.   3/40    5/32    5/32   10/40
2094 M f b6c eat 80w91 TR21 :                        0    .290mg  .560mg
 TBA MXB s      no dre   P=1.    -  .878mg n.s.s.   3/20   13/50    9/50
 liv MXB s      1.09mg \ P<.06      .446mg n.s.s.   0/20    6/50   (2/50)                                         liv:hpa,hpc,nnd.
 lun MXB s      5.05mg * P<.4       1.75mg n.s.s.   0/20    2/50    2/50                                              lun:a/a,a/c.
2095 M m b6c eat 80w91 TR21 :                        0    .260mg  .520mg
 TBA MXB s      1.06mg * P<.2    -  .399mg n.s.s.   4/20   14/50   18/50
 liv MXB s      1.04mg * P<.2       .422mg n.s.s.   3/20   12/50   16/50                                          liv:hpa,hpc,nnd.
 lun MXB s      24.7mg * P<.9       1.30mg n.s.s.   1/20    4/50    3/50                                              lun:a/a,a/c.
2096 M m b6c eat 80w89 TR21 : pool                   0    .260mg  .520mg
 liv hpc s      1.35mg * P<.08   a  .508mg n.s.s.  17/95   12/50   16/50
2097 M b c3e eat 24m24 20a                           0    1.25mg                                           Davis;txap,4,187-189;1962
 liv hpa e      4.09mg   P<.0005 +  2.40mg 10.6mg   9/134  36/148
 lun ade e      no dre   P=1.       27.8mg n.s.s.   3/134   1/148
 lun car e      no dre   P=1.       38.1mg n.s.s.   0/134   0/148
2098 M b c3e eat 24m24 22a                           0    1.25mg                        Epstein(review) {H J Davis};stev,4,1-52;1975
 liv hpt        3.08mg   P<.0005    1.95mg 6.43mg  27/200  69/200
 liv hpc        167.mg   P<.8       16.8mg n.s.s.   4/200   5/200
 tba ben        3.10mg   P<.0005    1.94mg 6.79mg  30/200  71/200
 tba mal        no dre   P=1.       24.7mg n.s.s.  21/200   9/200
2099 M f cf1 eat 26m26 89                            0    1.30mg                                         Thorpe;fctx,11,433-442;1973
 liv mix e      .567mg   P<.0005 +  .298mg 1.27mg  10/44   26/30
 liv lct e      1.59mg   P<.0005 +  .842mg 3.48mg   0/44   14/30
 lun tum e      no dre   P=1.    -  4.36mg n.s.s.  27/44    8/30
2100 M f cf1 eat 28m32 103a                          0    12.8ug  .124mg  1.30mg                         Walker;fctx,11,415-432;1973
 lun ade ae     .606mg Z P<.002  -  .300mg 2.84mg  48/297  23/90   30/87  (15/148)
 liv mix ae     .642mg * P<.0005 +  .481mg .870mg  39/297  24/90   32/87  136/148
 liv lpb ae     1.96mg Z P<.0005    1.49mg 2.66mg   0/297   4/90    5/87   81/148
 lun car ae     1.78mg Z P<.06   -  .624mg n.s.s.  18/297  12/90   12/87   (0/148)
2101 M f cf1 eat 25m30 103b                          0    .162mg  .325mg  .650mg  1.30mg  2.60mg
 liv mix aes    1.49mg * P<.0005 +  .959mg 2.69mg   8/78    5/30   12/28   18/30    9/17   16/21
 liv lpb aes    9.72mg * P<.0005    4.87mg 29.5mg   0/78    0/30    1/28    5/30    2/17    3/21
 lun ade aes    no dre   P=1.    -  2.03mg n.s.s.  24/78    7/30    3/28   (3/30    1/17    0/21)
 lun car aes    no dre   P=1.    -  30.6mg n.s.s.   8/78    0/30    0/28    1/30    0/17    0/21
2102 M f cf1 eat 90w90 103c                          0    1.30mg
 liv lpb e      2.59mg   P<.007     .978mg 31.8mg   0/22    5/22
 liv mix e      1.05mg   P<.02   +  .438mg n.s.s.   5/22   13/22
 lun ade e      no dre   P=1.    -  2.93mg n.s.s.   7/22    2/22
 lun car e      no dre   P=1.    -  4.41mg n.s.s.   0/22    0/22
2103 M f cf1 eat 30m30 103d                          0    1.30mg
 liv mix e      3.11mg   P<.02   +  1.20mg n.s.s.   3/28    8/19
 liv lpb e      12.1mg   P<.06      2.98mg n.s.s.   0/28    2/19
 lun ade e      no dre   P=1.    -  7.71mg n.s.s.   5/28    0/19
 lun car e      no dre   P=1.    -  7.71mg n.s.s.   0/28    0/19
2104 M f cf1 eat 25m25 103e                          0    1.30mg
 liv mix e      1.16mg   P<.002  +  .548mg 5.32mg   4/24   15/24
 liv lpb e      3.96mg   P<.007     1.50mg 51.4mg   0/24    5/24
 lun ade e      5.69mg   P<.4    -  1.41mg n.s.s.   4/24    7/24
 lun car e      no dre   P=1.    -  6.68mg n.s.s.   3/24    0/24
2105 M m cf1 eat 26m26 89                            0    1.20mg                                         Thorpe;fctx,11,433-442;1973
 liv mix e      noTD50   P<.0005 +  n.s.s. .469mg  11/45   30/30
 liv lct e      1.28mg   P<.0005 +  .682mg 3.03mg   2/45   16/30
 lun tum e      no dre   P=1.    -  2.87mg n.s.s.  27/45   11/30
2106 M m cf1 eat 28m31 103a                          0    11.8ug  .118mg  1.15mg                         Walker;fctx,11,415-432;1973
 liv mix ae     .547mg * P<.0005 +  .416mg .729mg  58/288  32/124  34/111 165/176
 liv lpb ae     1.68mg * P<.0005    1.29mg 2.25mg  12/288   5/124   9/111 100/176
 lun ade ae     2.13mg Z P<.5    -  .439mg n.s.s.  95/288  47/124  42/111 (32/176)
 lun car ae     3.71mg Z P<.4    -  .844mg n.s.s.  23/288  14/124  13/111  (2/176)
2107 M m cf1 eat 26m30 103b                          0    .150mg  .300mg  .600mg  1.20mg  2.40mg
 liv mix aes    1.12mg Z P<.0005 +  .714mg 2.09mg   9/78    6/30   13/30   26/30    5/11   12/17
 liv lpb aes    4.66mg * P<.0005    2.59mg 9.94mg   0/78    2/30    1/30    3/30    1/11    9/17
 lun ade aes    no dre   P=1.    -  3.96mg n.s.s.  45/78   17/30   11/30   14/30    2/11   (1/17)
 lun car aes    no dre   P=1.    -  14.7mg n.s.s.   1/78    1/30    1/30    1/30    0/11    0/17
2108 M m cf1 eat 30m30 103c                          0    1.20mg
 liv mix e      .913mg   P<.002  +  .420mg 3.87mg   8/23   20/24
 liv lpb e      5.12mg   P<.04      1.85mg n.s.s.   1/23    6/24
 lun ade e      no dre   P=1.    -  4.13mg n.s.s.   7/23    4/24
 lun car e      no dre   P=1.    -  8.99mg n.s.s.   0/23    0/24
2109 M m cf1 eat 30m30 103d                          0    1.20mg
 liv mix e      1.91mg   P<.04   +  .589mg n.s.s.   7/30    6/10
 liv lpb e      6.58mg   P<.2       1.41mg n.s.s.   1/30    2/10
 lun ade e      no dre   P=1.    -  2.93mg n.s.s.  13/30    1/10
 lun car e      no dre   P=1.    -  3.75mg n.s.s.   1/30    0/10
2110 M m cf1 eat 26m29 103e                          0    1.06mg
 liv mix e      .713mg   P<.002  +  .305mg 3.96mg  10/24   19/22
 liv lpb e      4.02mg   P<.006     1.52mg 35.7mg   0/24    5/22
 lun ade e      no dre   P=1.    -  1.93mg n.s.s.  11/24    8/22
 lun car e      no dre   P=1.    -  6.86mg n.s.s.   1/24    0/22
2111 R b osm eat 24m24 23                            0    22.5ug  90.0ug  .450mg  2.25mg  4.50mg  6.75mg    Fitzhugh;fctx,2,551-562;
                                                                                                                                1964
 lun lys es     no dre   P=1.       35.4mg n.s.s.   1/17    4/22    2/23    2/18    1/20    0/18    0/11
 tba mix es     no dre   P=1.    +  23.3mg n.s.s.   3/17    8/22    8/23    4/18    4/20    3/18    0/11
2112 R f osm eat 21m26 TR21 :                        0    1.10mg  1.70mg
 TBA MXB sv     no dre   P=1.    -  .635mg n.s.s.   7/10   39/50  (27/50)
 liv MXB sv     38.4mg * P<.8       9.44mg n.s.s.   0/10    1/50    1/50                                          liv:hpa,hpc,nnd.
2113 R f osm eat 21m25 TR21 : pool                   0    1.10mg  1.70mg
 adr MXA sv#    4.42mg \ P<.003  -  1.80mg 22.2mg   0/60    6/50   (2/50)                                             adr:coa,coc. S
2114 R f f34 eat 24m24 TR22 :                        0    .100mg  .500mg  2.50mg
 TBA MXB a      489.mg * P<1.    -  1.62mg n.s.s.  17/24   17/24   16/24   14/24
 liv MXB a      no dre   P=1.       n.s.s. n.s.s.   0/24    0/24    0/24    0/24                                  liv:hpa,hpc,nnd.
2115 R f osm eat 28m29 1004                          0    .960mg  1.44mg  2.40mg                      Deichmann;imed,39,426-434;1970
 liv tum ev     no dre   P=1.    -  6.19mg n.s.s.   0/88    0/48    0/41    0/41
 tba mix ev     no dre   P=1.    -  15.1mg n.s.s.  60/88   23/48   16/41   16/41
2116 R m osm eat 21m26 TR21 :                        0    .880mg  1.36mg
 TBA MXB sv     3.34mg * P<.6    -  .774mg n.s.s.   5/10   24/50   22/50
 liv MXB sv     no dre   P=1.       7.38mg n.s.s.   1/10    0/50    1/50                                          liv:hpa,hpc,nnd.
2117 R m f34 eat 24m24 TR22 :                        0    80.0ug  .400mg  2.00mg
 TBA MXB a      7.28mg * P<.4    -  1.64mg n.s.s.   5/24    9/24    7/24    9/24
 liv MXB a      no dre   P=1.       n.s.s. n.s.s.   0/24    0/24    0/24    0/24                                  liv:hpa,hpc,nnd.
2118 R m osm eat 29m29 1004                          0    .768mg  1.15mg  1.92mg                      Deichmann;imed,39,426-434;1970
 liv hem ev     no dre   P=1.    -  4.90mg n.s.s.   1/75    0/48    0/38    0/44
 tba mix ev     no dre   P=1.    -  8.93mg n.s.s.  19/75    4/48    7/38   (1/44)
2119 R f cfe eat 24m24 100                           0    5.00ug  50.0ug  .500mg                      Stevenson;txap,36,247-254;1976
 tba mix e      no dre   P=1.    -  .388mg n.s.s.  18/43   18/23   16/23   13/23
2120 R m cfe eat 24m24 100                           0    4.00ug  40.0ug  .400mg
 tba mix e      2.01mg * P<.5    -  .384mg n.s.s.  12/43    9/23    5/23    9/23
2121 R f nss eat 24m24 1002                          0    .125mg  .625mg  1.25mg                      Cleveland;aenh,13,195-198;1966
 tba tum        57.2mg * P<.9    -  3.29mg n.s.s.   6/60    7/40    7/40    5/40
2122 R m nss eat 24m24 1002                          0    .100mg  .500mg  1.00mg
 tba tum        40.5mg * P<.8    -  4.09mg n.s.s.   3/60    1/40    3/40    2/40

Mutagenicity in Salmonella: negative
SMILES Code for Dieldrin: Cl\C2=C(/Cl)C3(Cl)C1C4CC(C1C2(Cl)C3(Cl)Cl)C5OC45
InChI Code for Dieldrin: InChI=1/C12H8Cl6O/c13-8-9(14)11(16)5-3-1-2(6-7(3)19-6)4(5)10(8,15)12(11,17)18/h2-7H,1H2
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database

Chemical Structure for Dieldrin:

Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
A Screen version plot for use on a single computer screen, with the same data.
Excel version of the same data.
Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD₁₀ (LTD₁₀) are readily calculated from the TD₅₀ and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD₁₀ values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact slone.cpdb@gmail.com.
Last updated: October 3, 2007